Sabitlenmiş Tweet

eXoZymes (NASDAQ: $EXOZ) Chief Commercial Officer Damien Perriman discussed the company’s NCT pilot-scale manufacturing milestone and broader commercialization strategy for cell-free biomanufacturing in a @Nasdaq interview filmed at the Nasdaq market site in New York City.
@eXoZymes Inc. is a @b2idigital Featured Company. See the company’s profile at b2idigital.com/exozymes-1.
Interview Highlights:
• 100x pilot-scale manufacturing campaign completed with Cayman Chemical, transferring the company’s process to Cayman’s operators and facility in Michigan
• 99% conversion of raw material to final product
• 99.6% purity achieved in the pilot run
• 12 months from initial development to 100x pilot scale
Perriman also discussed plans for additional human use studies on NCT, completion of the company’s GRAS dossier, potential partnerships with marketing players to bring NCT to market, and ongoing work to modify enzymes to create NCT analogues for pharmaceutical applications. He noted that Santalene is already under development as the next product in the company’s pipeline.
“We’ve shown that we can go from idea to 100× pilot scale in 12 months — and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine,” said Damien Perriman, Chief Commercial Officer of eXoZymes.
Watch the Nasdaq interview: exozymes.twentythree.com/nasdaq-damien-…
Read the company’s post: exozymes.com/blog/perriman-…
About eXoZymes: eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical and cell-based production methods, with technology validated through publications in Nature Communications and Nature Chemical Biology.
eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.
To learn more about eXoZymes, visit exozymes.com. For investor inquiries, visit exozymes.com/investor.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at b2idigital.com.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser.
English